Synopsis

Analysis and opinion on monthly deal activity, along with the trend for the last six months for merger and acquisition (M&A), private equity, private placement, IPO, and secondary offering deals.

Introduction

This report contains extensive qualitative and quantitative analysis of monthly deal activity (including strategic alliances) in the biotechnology, healthcare services, medical devices, and pharmaceuticals sectors across global markets, with a specific focus on key emerging markets. It offers insights into deal activity, deal rationale, and valuation trends.

Scope

• Insights into deal activity across M&A, private equity, private placement, IPO, and secondary offering deals 
• In-depth analysis on all key sectors, namely biotechnology, healthcare services, medical devices, and pharmaceuticals
• Geographical trends by primary regions and by key emerging markets
• Detailed analysis of the deal activity during the month, along with the trend for the last six months by deal volume and value

Highlights

• The pharmaceutical and healthcare sector recorded 95 M&A transactions worth $5.1bn in September 2008, witnessing a decline of 25.2% and 79.1% in volume and value terms, respectively, as compared to the six-month (Mar 2008–Aug 2008) average. M&A activity in the biotechnology sector was aimed at strengthening late stage development product pipeline to replenish deleting product portfolios.
• M&A activity in the healthcare services segment was driven by home healthcare service providers and assisted living facility operators. The pharmaceutical sector witnessed cross-border transactions focused primarily on the US and emerging markets. Deal activity in the medical devices segment was driven by investments in cardiovascular and spine market.
• Venture capitalists invested over $756.3m in 87 companies, a decrease of 19.8% in value terms as compared to the last six-month average, driven by investments in biotechnology sectors.
• The sector recorded five public offerings, a decrease of 52.4% as compared to the six-month average. Private placement deals decreased by 57.1% and 10.1% in volume and value terms, respectively, as compared with the last six-month average.

Reason to Purchase

• Understand which sectors are experiencing the most activity, and which type of investor, and advisor are playing the significant roles
• Find out how key deals are changing the competitive landscape of your business 
• Find out how companies in pharmaceuticals and healthcare industry are raising funds through capital markets, private equity, and private placement deals

View Table Of Contents >